Chongqing Zhifei Biological Products Co., Ltd.
Pharmaceutical industry · Chongqing, Chongqing
About Chongqing Zhifei Biological Products Co., Ltd.
Chongqing Zhifei Biological Products Co., Ltd., known simply as Zhifei, is a Chinese biopharmaceutical company specialising in vaccines for human use, active in the biological products industry since 2002 and headquartered in Chongqing. In September 2010 it listed on the Shenzhen Stock Exchange (stock code 300122), becoming the first privately run vaccine enterprise listed on the ChiNext board, a milestone that confirmed its place among China's leading vaccine manufacturers.
The company integrates research and development, production, marketing, distribution and import and export of vaccines across a single full industry chain. Its proprietary portfolio includes the Recombinant Novel Coronavirus Vaccine (CHO Cell), the recombinant Mycobacterium tuberculosis fusion protein marketed as Ekear, the Haemophilus influenzae type b vaccine XiFeiBei, the Group ACYW135 Meningococcal Polysaccharide Vaccine Menwayc, Mycobacterium Vaccae for Injection (Vaccae) and the Meningococcal Group A and C Polysaccharide Conjugate Vaccine. Through its subsidiaries Beijing Zhifei Lvzhu and Anhui Zhifei Longcom it advances a rich pipeline against meningitis, tuberculosis, pneumonia, influenza, rabies and norovirus, and it is also the sole distributor in China of MSD vaccines such as Gardasil, RotaTeq, Pneumovax 23 and Vaqta.
Zhifei supports its commercial reach with a service network covering more than 30,000 points of vaccination across over 2,600 districts and counties in more than 300 cities throughout China's 31 provinces, autonomous regions and municipalities, backed by its own GSP-compliant cold chain with real-time temperature monitoring. Guided by its philosophy of putting social benefits before corporate profits, the company works to raise public awareness of disease prevention and to strengthen public health in China and abroad.
The company integrates research and development, production, marketing, distribution and import and export of vaccines across a single full industry chain. Its proprietary portfolio includes the Recombinant Novel Coronavirus Vaccine (CHO Cell), the recombinant Mycobacterium tuberculosis fusion protein marketed as Ekear, the Haemophilus influenzae type b vaccine XiFeiBei, the Group ACYW135 Meningococcal Polysaccharide Vaccine Menwayc, Mycobacterium Vaccae for Injection (Vaccae) and the Meningococcal Group A and C Polysaccharide Conjugate Vaccine. Through its subsidiaries Beijing Zhifei Lvzhu and Anhui Zhifei Longcom it advances a rich pipeline against meningitis, tuberculosis, pneumonia, influenza, rabies and norovirus, and it is also the sole distributor in China of MSD vaccines such as Gardasil, RotaTeq, Pneumovax 23 and Vaqta.
Zhifei supports its commercial reach with a service network covering more than 30,000 points of vaccination across over 2,600 districts and counties in more than 300 cities throughout China's 31 provinces, autonomous regions and municipalities, backed by its own GSP-compliant cold chain with real-time temperature monitoring. Guided by its philosophy of putting social benefits before corporate profits, the company works to raise public awareness of disease prevention and to strengthen public health in China and abroad.